Off-label topical calcineurin inhibitor use in children

Area of Science:

• Pediatric Dermatology
• Pharmacovigilance
• Drug Safety Regulation

Background:

• Topical calcineurin inhibitors (TCIs), tacrolimus and pimecrolimus, are used for inflammatory skin conditions.
• Regulatory actions were taken by the US FDA in 2005 regarding TCI use in children.
• Assessing TCI utilization patterns in pediatric populations is crucial for understanding drug safety and efficacy.

Purpose of the Study:

• To evaluate the off-label use of topical calcineurin inhibitors (TCIs) in pediatric patients.
• To compare TCI usage patterns before and after the 2005 US FDA regulatory actions.
• To analyze the impact of regulatory actions on TCI prescribing for atopic dermatitis in children.

Main Methods:

• Retrospective analysis of US Medicaid data from 2001-2009.
• Identification of new pediatric users (<20 years) of topical tacrolimus or pimecrolimus.
• Assessment of drug utilization rates, age distribution, and prior/concurrent diagnoses and therapies.

Main Results:

• A substantial decrease in TCI use was observed in children younger than 2 years post-FDA action.
• The proportion of new users under 2 years decreased significantly for both tacrolimus (36.7% to 22.5%) and pimecrolimus (47.0% to 33.7%).
• Off-label use as first-line therapy for atopic dermatitis showed minimal change, with a slight increase in prior topical corticosteroid use.

Conclusions:

• FDA regulatory action in 2005 led to a significant reduction in TCI use among very young children.
• The study indicates that off-label TCI use as a primary treatment for atopic dermatitis in children was minimally affected by regulatory changes.